secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001104659-23-124911
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH
--------------------------------------------------------------------------------

- Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma
- CNTY-101 was generally well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed
- Pharmacokinetic data suggested CNTY-101 exposure maintained upon additional cycles without lymphodepletion due to lack of allo-rejection
- Company to host conference call Dec 11 to review additional clinical results from Dose Levels 1 and 2 and plans for systemic lupus erythematosus

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/0001104659-23-124911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/tm2332547d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer